The Ipamorelin + CJC-1295 Stack: Complete Protocol Guide

The Ipamorelin + CJC-1295 stack is arguably the most widely used peptide combination in the GH optimization space, and for good reason - it represents one of the most mechanistically coherent and evidence-supported approaches to augmenting endogenous growth hormone secretion without the complexity, cost, or regulatory issues of exogenous recombinant HGH.

This guide covers the pharmacology of each compound, why they work synergistically, the critical decision between CJC-1295 with and without DAC, practical dosing protocols, expected effects, and monitoring recommendations.

Ipamorelin: Selective GHRP

Ipamorelin is a synthetic pentapeptide and growth hormone releasing peptide (GHRP). It works by binding to the ghrelin receptor (GHSR-1a) in the pituitary and hypothalamus, stimulating a pulse of growth hormone secretion. What distinguishes Ipamorelin from earlier GHRPs (GHRP-2, GHRP-6) is its selectivity:

• Minimal cortisol stimulation: Earlier GHRPs significantly increase cortisol output. Ipamorelin does not produce meaningful cortisol elevation at standard doses - a clinically important distinction for long-term use.
• Minimal prolactin stimulation: GHRP-6 in particular raises prolactin; Ipamorelin largely avoids this.
• No significant hunger stimulation: GHRP-6 is notorious for intense hunger response via its ghrelin-mimetic properties. Ipamorelin produces far less appetite stimulation.
• Short half-life (~2 hours): Produces a discrete pulse rather than continuous stimulation, preserving pulsatile GH physiology.

CJC-1295: GHRH Analog

CJC-1295 is a synthetic analog of growth hormone releasing hormone (GHRH) - the hypothalamic signal that primes the pituitary for GH release. It works via a completely different receptor (GHRHR) than Ipamorelin.

DAC vs. No DAC: A Critical Distinction

Property	CJC-1295 (no DAC)	CJC-1295 (with DAC)
Half-life	~30 minutes	~8 days
GH release pattern	Pulsatile (physiologic)	Continuous bleed (non-physiologic)
Dosing frequency	2-3x daily	1-2x weekly
Receptor desensitization risk	Low	Moderate - higher with chronic use
IGF-1 elevation pattern	Modest, pulse-dependent	Sustained, significant bleed elevation
Recommended for	Physiologic GH optimization	Higher IGF-1 target, less frequent injection

The majority of practitioners focused on physiologic GH enhancement prefer CJC-1295 without DAC (sometimes sold as "Mod GRF 1-29") to preserve the natural pulsatile character of GH secretion. CJC-1295 with DAC produces a prolonged, lower-level elevation in GHRH stimulation that some find more convenient but that carries greater risk of receptor downregulation with extended use.

Why the Stack Works: Synergistic Amplification

The GHRH + GHRP combination is not merely additive - it is synergistic. This is one of the better-established findings in GH secretagogue pharmacology:

• GHRH (CJC-1295) primes the somatotroph cells of the pituitary to secrete GH - it increases the available pool of releasable GH
• GHRP (Ipamorelin) triggers the actual release event via the ghrelin receptor
• When administered together, the GH pulse produced is substantially larger than either compound alone - studies in healthy adults have shown 2-10x greater GH pulse amplitude with combination versus either compound alone

This is why the stack has become the standard protocol rather than using either compound independently.

Dosing Protocol

Standard Starting Protocol (no DAC)

• Ipamorelin: 100-200 mcg per dose
• CJC-1295 (no DAC): 100-200 mcg per dose
• Frequency: 1-3x daily; most practitioners use once daily (before sleep) or twice daily (before sleep + morning)
• Timing: On an empty stomach - elevated insulin from carbohydrate consumption blunts GH secretion; allow 1.5-2 hours post-meal before dosing
• Duration before food: Wait 30-60 minutes after injection before eating

Preferred Dosing Window

Before sleep is the most commonly recommended primary dosing window, for two reasons:

1. The largest natural GH pulse occurs approximately 1-2 hours after sleep onset; peptide dosing can amplify this pulse
2. Fasting during sleep eliminates the insulin interference issue without requiring intentional fasting

Cycling

Standard community practice: 8-12 weeks on, 4-6 weeks off. The rationale is prevention of receptor desensitization and maintenance of pituitary sensitivity to endogenous GHRH and ghrelin signals. No robust clinical data defines the optimal cycle length; 12 weeks on / 4 weeks off is the most common protocol.

Expected Effects and Timeline

Timeframe	Commonly Reported Effects
Weeks 1-2	Improved sleep quality and depth, mild water retention in some users
Weeks 2-4	Increased recovery speed, reduced soreness after training
Weeks 4-8	Gradual lean body composition changes, improved skin quality
Weeks 8-12	Continued body composition benefits, potential IGF-1 elevation measurable on bloodwork

Effects are gradual and subtle compared to exogenous HGH. This is expected - the stack works by amplifying endogenous GH secretion, not replacing it. Users who expect dramatic body recomposition on a 12-week cycle without training and nutrition optimization will be disappointed.

Side Effects and Risk Management

• Water retention: Common, particularly early in the cycle. Usually resolves; reduce carbohydrate timing around injections if persistent.
• Tingling or numbness in extremities: Reported by some users, likely related to fluid shifts. Usually transient.
• Hunger: Less pronounced than with GHRP-6 but possible, particularly with higher Ipamorelin doses.
• Fasting glucose elevation: GH has anti-insulin effects; monitor fasting glucose if metabolic health is a concern, particularly in pre-diabetic individuals.
• Headache: Occasionally reported; usually mild and transient in the first 1-2 weeks.

Biomarkers to Monitor

• IGF-1: Primary surrogate for GH exposure over time. Test at baseline and at week 8-10. Moderate elevation (within upper-normal range for age) is the target; supraphysiologic elevation is a signal to reduce dose.
• Fasting glucose and insulin: Baseline and at week 8, particularly for individuals with metabolic risk factors.
• TSH and free thyroid hormones: GH axis upregulation can affect thyroid function in some individuals. Annual monitoring is reasonable.

Evidence grade: B. Strong mechanistic rationale, good preclinical data, reasonable human data on GH secretagogue combinations. Limited long-term safety data beyond 6-month study periods. Not FDA approved for this application.